ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
62 announcements with these filters
Advanced Enzyme Technologies announced an open market buyback of up to 13.94 lakh shares at a maximum price of ₹500 per share.
Advanced Enzyme Technologies is investing ₹2 Crore in its wholly-owned subsidiary, Advanced Nutrazyme Private Limited. This capital infusion supports the subsidiary's ongoing business operations.
Advanced Enzyme Technologies Limited will acquire the remaining 4.28% stake in JC Biotech Private Limited for ₹7.98 Crore, making it a wholly-owned subsidiary.
Advanced Enzyme Technologies Limited's board approved a buyback of up to 1.39 million shares worth ₹69.7 Crore via the open market to optimize capital.
Advanced Enzyme reported Q1 FY27 revenue of ₹1,898 mn, up 2% YoY, despite a 10% EBITDA decline. Segment performance was mixed, with specialized manufacturing and bio-processing showing strong growth.
Advanced Enzyme Technologies announced its Q1 FY27 consolidated financial highlights. Consolidated revenue from operations stood at ₹189.8 Crore for the quarter.
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹189.8 Cr (+2.1% YoY) and net profit of ₹38.6 Cr (-4.5% YoY) for Q1 FY27.
Advanced Enzyme Technologies Ltd scheduled a board meeting for August 08, 2026, to consider Q1 FY27 financial results and a proposal for a share buyback.
Advanced Enzyme Technologies Ltd held its 37th Annual General Meeting on July 31, 2026, to discuss and vote on various ordinary and special business resolutions.
Advanced Enzyme Technologies filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.
Board recommended Rs.1.35/share dividend and director reappointments for AGM. Related party transactions with subsidiary and relative also approved.
Advanced Enzyme Technologies Ltd filed its Integrated Annual Report for FY 2025-26. The report highlights ₹7,458 million revenue and 1,736 million PAT.
Advanced Enzyme Technologies filed its BRSR for FY2025-26, detailing operations and CSR. The report covers employee data, subsidiaries, and sustainability risks without financial surprises.
Advanced Enzyme Technologies Ltd. is convening its 37th AGM on July 31, 2026. The agenda includes financial statements, dividend declaration, and director appointments.
Advanced Enzyme Technologies set July 24, 2026, as record date for a ₹1.35/share final dividend, pending AGM approval. Payment expected after August 3, 2026.
Ms. Rajshree Patel ceased as Independent Director after her second term ended. The company's board composition changes accordingly.
Advanced Enzyme Technologies completed a ₹0.25 Crore investment in its subsidiary, Advanced Nutrazyme. The investment was executed via a rights issue of 2,50,000 equity shares.
Advanced Enzyme Technologies filed its Annual Secretarial Compliance Report for FY2026. The auditor confirmed full compliance with SEBI regulations with no adverse observations reported.
Advanced Enzyme reported its highest-ever quarterly and annual revenue for FY26. Management focused on expanding R&D, human healthcare flagship growth, and navigating global supply chain disruptions.
Advanced Enzyme delivered its highest ever quarterly revenue with robust double-digit growth across all segments. However, management remains cautious about global inflationary pressures on energy and logistics costs potentially impacting near-term margins.
Advanced Enzyme Technologies recommended a final dividend of ₹1.35 per share for FY 2025-26. The record date and AGM details will be announced later.
Advanced Enzyme Technologies approved the re-appointment of Executive Director Mukund Kabra and Statutory Auditors. Additionally, Pradip Shah was appointed as an Independent Director for five years.
Advanced Enzyme Technologies allotted 49,350 equity shares under its employee stock option scheme. This marginal capital expansion reflects ongoing employee benefit plan executions.
Advanced Enzyme Technologies reported ₹745.8 Crore annual revenue, up 17% YoY. FY26 PAT grew 30% to ₹173.6 Crore, demonstrating robust operational performance and margin expansion.
Advanced Enzyme reported strong FY26 performance with 17% revenue growth and 30% PAT growth, driven by Human and Animal Nutrition segments and record margins.
Advanced Enzyme reported strong Q4FY26 results with 22% YoY revenue growth and 69% YoY PAT growth. Focus remains on expanding human and animal nutrition segments globally.
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹203.4 Cr (+21.7% YoY) and net profit of ₹45.3 Cr (+69.7% YoY) for Q4 FY26.
Advanced Enzyme Technologies reported FY26 annual results and recommended a ₹1.35 per share final dividend. The board also approved director re-appointments and auditor extensions.
Advanced Enzyme Technologies Ltd received credit rating reaffirmations from CRISIL for ₹100 Crore in bank facilities. The long-term rating is CRISIL A+/Stable and short-term rating is CRISIL A1+, reflecting maintained creditworthiness.
Advanced Enzyme Technologies Limited has scheduled a Board meeting on May 09, 2026, to approve audited financial results for FY2026 and consider recommending final and interim dividends. The trading window for company securities remains closed until May 11, 2026.